PMID- 31564880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 15
DP  - 2019
TI  - Efficacy of ginkgo biloba extract as augmentation of venlafaxine in treating 
      post-stroke depression.
PG  - 2551-2557
LID - 10.2147/NDT.S215191 [doi]
AB  - BACKGROUND: Post-stroke depression (PSD) is one of the most common psychiatric 
      diseases afflicting stroke survivors. This study was conducted to assess the 
      efficacy of ginkgo biloba extract as augmentation of venlafaxine in treating PSD. 
      METHODS: The included PSD patients were randomly assigned into the experiment 
      group (receiving ginkgo biloba extract plus venlafaxine) and control group 
      (receiving venlafaxine alone). The treatment was continued for eight weeks. The 
      Hamilton Depression Rating Scale (HDRS) and the Self-rating Depression Scale 
      (SDS) were used to assess the depressive symptoms. The National Institutes of 
      Health Stroke Scale (NIHSS) was used to assess the neurological defect, and the 
      Activities of Daily Living (ADL) was used to assess recovery of abilities of 
      patients after stroke. Meanwhile, the levels of serum 5-hydroxytryptamine (5-HT) 
      and brain-derived neurotrophic factor (BDNF) were measured before and after 
      treatment. The dose of venlafaxine used and adverse events were also recorded. 
      RESULTS: Each group had 40 PSD patients. After treatment, the depressive 
      symptoms, neurological defect and living function were significantly improved in 
      both groups. But the patients receiving ginkgo biloba extract plus venlafaxine 
      had the significantly lower average HDRS score (p=0.0008), SDS score (p<0.00001), 
      NIHSS score (p=0.00001), and higher average ADL score (p=0.0005). Meanwhile, 
      compared to the control group, patients in the experiment group had the 
      significantly higher 5-HT (p<0.00001) level and BDNF level (p<0.00001), needed 
      lower dose of venlafaxine (p=0.007), and experienced fewer adverse events. 
      CONCLUSION: These results demonstrated that the ginkgo biloba extract was a good 
      augmentation of venlafaxine in treating PSD and should be further investigated.
CI  - (c) 2019 Liang et al.
FAU - Liang, Zi-Hong
AU  - Liang ZH
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
FAU - Jia, Yan-Bo
AU  - Jia YB
AD  - Department of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Huhhot, Inner Mongolia, People's Republic of China.
FAU - Wang, Mei-Ling
AU  - Wang ML
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
FAU - Li, Zi-Ru
AU  - Li ZR
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
FAU - Li, Min
AU  - Li M
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
FAU - Yun, Yong-Li
AU  - Yun YL
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
FAU - Zhu, Run-Xiu
AU  - Zhu RX
AD  - Department of Neurology, Inner Mongolia Autonomous Region People's Hospital, 
      Huhhot, Inner Mongolia, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190903
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC6731991
OTO - NOTNLM
OT  - PSD
OT  - ginkgo biloba extract
OT  - post-stroke depression
OT  - venlafaxine
COIS- The authors declare no financial or other conflicts of interest in this work.
EDAT- 2019/10/01 06:00
MHDA- 2019/10/01 06:01
PMCR- 2019/09/03
CRDT- 2019/10/01 06:00
PHST- 2019/05/10 00:00 [received]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/10/01 06:00 [entrez]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2019/10/01 06:01 [medline]
PHST- 2019/09/03 00:00 [pmc-release]
AID - 215191 [pii]
AID - 10.2147/NDT.S215191 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2019 Sep 3;15:2551-2557. doi: 10.2147/NDT.S215191. 
      eCollection 2019.